ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc (VRTX)

516,74
14,29
(2,84%)
Geschlossen 11 November 10:00PM
516,91
0,17
(0,03%)
Nach Börsenschluss: 1:26AM

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
516,91
Gebot
515,55
Fragen
550,00
Volumen
1.273.723
504,94 Tagesbereich 519,88
341,90 52-Wochen-Bereich 516,91
Marktkapitalisierung
Handelsende
502,45
Handelsbeginn
508,60
Letzte Trade
3
@
518.36
Letzter Handelszeitpunkt
Finanzvolumen
US$ 657.005.633
VWAP
515,8152
Durchschnittliches Volumen (3 Mio.)
1.033.863
Ausgegebene Aktien
258.102.203
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
37,35
Gewinn pro Aktie (EPS)
13,83
Erlöse
9,92B
Nettogewinn
3,57B

Über Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In add... Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Boston, Massachusetts, USA
Gegründet
-
Vertex Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VRTX. The last closing price for Vertex Pharmaceuticals was US$502,45. Over the last year, Vertex Pharmaceuticals shares have traded in a share price range of US$ 341,90 to US$ 516,91.

Vertex Pharmaceuticals currently has 258.102.203 shares in issue. The market capitalisation of Vertex Pharmaceuticals is US$129,68 billion. Vertex Pharmaceuticals has a price to earnings ratio (PE ratio) of 37.35.

Option-Flow Vertex Pharmaceuticals (VRTX)

Gesamtfluss

Bullisch

Nettoprämie

3M

Calls / Puts

366,67%

Käuf. / Verkä.

133,33%

OTM / ITM

94,44%

Sweeps

1,43%

VRTX Neueste Nachrichten

Vertex Reports Third Quarter 2024 Financial Results

— Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term...

Vertex to Participate in Upcoming November Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Officer and President...

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

- New data on povetacicept 80 mg SC Q4 weeks in IgA nephropathy shows mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving...

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

-- Phase 3 abstract selected for presentation in “Best Abstract” session -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3...

Vertex to Announce Third Quarter 2024 Financial Results on November 4th

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
145.859.73336729928471.06516.91463.14461375088488.2829416CS
438.388.02039579546478.53516.91463.14461094254482.46320286CS
1245.2559.59493697724471.655516.91447.7251033863476.75090105CS
26103.5825.0598795152413.33516.91412.121119281473.08570136CS
52136.335.8109350779380.61516.91341.91218903435.93425856CS
156323.92167.842893414192.99516.91179.961361342331.03716809CS
260319.83162.284351532197.08516.91176.361541517281.22445493CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
INODInnodata Inc
US$ 42,75
(75,64%)
9,61M
SEZLSezzle Inc
US$ 428,58
(71,11%)
632,22k
SONDSonder Holdings Inc
US$ 4,36
(60,89%)
1,42M
INDIindie Semiconductor Inc
US$ 5,50
(60,35%)
36,22M
AZIAutozi Internet Technology Global Ltd
US$ 2,54
(55,83%)
13,41M
PRPHProPhase Labs Inc
US$ 0,78
(-45,45%)
2,66M
ELWSEarlyworks Co Ltd
US$ 3,69
(-45,33%)
857,59k
ALVRAlloVir Inc
US$ 0,6103
(-37,82%)
2,16M
CHSNChanson International Holding
US$ 5,66
(-37,60%)
530,53k
RVNCRevance Therapeutics Inc
US$ 3,705
(-35,90%)
13,15M
ELABElevai Labs Inc
US$ 0,0188
(5,03%)
434,16M
TIVCTivic Health Systems Inc
US$ 0,4003
(53,67%)
291,1M
TSLATesla Inc
US$ 321,22
(8,19%)
203,89M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 19,06
(16,29%)
187,02M
NVDANVIDIA Corporation
US$ 147,63
(-0,84%)
175,09M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock